Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Paclitaxel 9Fluorouracil 9Cisplatin 9Radiotherapy 8Oxaliplatin 6Irinotecan 5Leucovorin 4Docetaxel 4Cetuximab 4Carboplatin 3Taxes 2Surgical Procedures, Operative 2Polymerase Chain Reaction 2Filgrastim 2Capecitabine 2uridine triacetate 1pegylated granulocyte colony-stimulating factor, human 1pegfilgrastim 1durvalumab 1carfilzomib 1atezolizumab 1Vorinostat 1Sorafenib 1Radiosurgery 1Psychiatric Rehabilitation 1Preoperative Exercise 1Platinum 1Lithium 1Granulocyte Colony-Stimulating Factor 1Gene Expression Profiling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Esophageal Neoplasms × AMG 337 × Clear all
NCT02344810 2023-05-25

C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer

Eastern Cooperative Oncology Group

Phase 1/2 Withdrawn
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gastrointestinal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡